GeneOne Life Science amends capital increase plan
진원생명과학
011000
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2797
Risk-adjusted indicator based on 2797 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Total Capital Increase (Original): 15,000,000,060 KRW
- • Total Capital Increase (Amended): 15,000,000,000 KRW
- • Operating Funds (Amended): 11,000,000,000 KRW
- • Debt Repayment Funds (Amended): 1,900,000,000 KRW
- • Other Funds (Amended): 4,000,000,000 KRW
- • New Share Issuance Price: 2,410 KRW per share
- • Maximum Dilution Rate: Not calculable without total shares outstanding
AI Analysis Summary
GeneOne Life Science has amended its paid-in capital increase plan, originally submitted on August 4, 2026. The total funding remains approximately 15 billion KRW, but the allocation has changed. Operating funds are now 11 billion KRW (down from 13.1 billion KRW), debt repayment funds are 1.9 billion KRW (up from 1.9 billion KRW, but previously part of a larger operating fund), and 4 billion KRW is allocated for 'other funds' (newly added for pre-maturity convertible bond acquisition and resale). The new share issuance price is 2,410 KRW, calculated with a 10% discount from the adjusted reference price of 2,670 KRW (5x the pre-suspension closing price of 534 KRW due to a 5:1 stock consolidation). The maximum shareholder dilution cannot be precisely calculated without the total number of shares outstanding, but the third-party allocation will result in a change of the largest shareholder to Revolt Investment Association (25.51% ownership) from Dongban Growth Investment Association No. 1 (8.49%). The shares will be subject to a one-year lock-up period. The amendment indicates a shift in funding priorities, with a new focus on managing convertible bonds, which could be a positive for long-term debt management but the overall dilution and change in funding purpose could be seen as negative.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.